Pharmaceutical

Express Scripts-Medco deal approved by U.S. regulators

April 2, 2012
Bloomberg News
Express Scripts Inc.’s $29.1 billion bid for rival drug benefit manager Medco Health Solutions Inc. won unconditional approval from U.S. antitrust regulators, clearing the way to create the biggest manager of prescription-drug benefits for corporate and government clients.
More

Lilly receives Europe's OK for new Byetta use

March 23, 2012
 IBJ Staff and Associated Press, Associated Press
European regulators have approved an expanded use for the diabetes treatment Byetta, developed by Eli Lilly and Co. and Amylin Pharmaceuticals Inc. The FDA approved the same expanded use last fall.
More

Lilly to focus on cancer, diabetes in China, CEO says

March 20, 2012
Bloomberg News
Indianapolis-based Eli Lilly and Co. will introduce “over a dozen” new products in China in the next five years, focusing on “unmet needs” such as cancer and diabetes, CEO John Lechleiter said this week.
More

Express Scripts’ Medco deal may be delayed by potential suit

March 19, 2012
 IBJ Staff and Bloomberg News
Express Scripts Inc.’s bid to acquire Medco Health Solutions Inc. and create the largest U.S. pharmacy-benefits manager may be delayed by a lawsuit being considered by five states.
More

Endocyte pulls trigger on European drug submission

March 13, 2012
J.K. Wall
Endocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after the European Commission granted it orphan drug status.
More

FTC asks critics of Express Scripts-Medco deal for ideas

March 10, 2012
Bloomberg News
Two pharmacy groups opposing Express Scripts Inc.’s proposed acquisition of Medco Health Solutions Inc. said they were asked by the U.S. Federal Trade Commission to suggest ways to revise the $29.1 billion deal so it wouldn’t harm competition.
More

FDA removes hurdle in Endocyte's path to drug approval

March 5, 2012
J.K. Wall
Endocyte Inc. can start enrolling patients again in a clinical trial of its experimental cancer drug, the company announced Monday, clearing away a hurdle to getting the drug approved in Europe.
More

New drugmaker code deprives docs of football, lunch for 2

March 1, 2012
Bloomberg News
Doctors can still get free samples of medicines, but not football tickets or lunch for their spouses, under a revised code of conduct drafted by a global drug industry trade group that counts Eli Lilly as a member.
More

Lilly plans 200 jobs at new $440M Ireland plant

February 27, 2012
 IBJ Staff and Bloomberg News
Eli Lilly and Co. plans to invest about $440 million in a new pharmaceutical plant at an existing company site in County Cork in southern Ireland. The facility in Kinsale will require as many as 200 skilled employees when fully operational.
More

Drugmakers singing same song: 2012 will be tough

February 2, 2012
Associated Press
For drugmakers, the golden era of the 1990s and early part of the last decade, when they seemed to effortlessly churn out new multibillion-dollar pills for the masses along with double-digit quarterly profit increases, is not even in the rearview mirror any more.
More

Lilly eying deal with Turkish drug company

January 31, 2012
Bloomberg News
Eli Lilly and Co. is among about a half-dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in a deal that may value the Turkish drugmaker at $1 billion, sources say.
More

Lilly's ex-partner wins FDA approval for diabetes drug

January 29, 2012
Bloomberg News
Amylin Pharmaceuticals Inc. and Alkermes Plc have gained U.S. clearance for Bydureon, a once-weekly diabetes shot. Eli Lilly and Co. co-developed the drug, but ended its partnership with Amylin last year.
More

Indiana Senate panel backs limits on abortion pill

January 25, 2012
Associated Press
The Senate health committee voted 5-4 in support of the bill that requires that a doctor examine a woman in person before giving her RU-486, provide written information about the physical risks of abortion and to schedule a follow-up ultrasound.
More

Deal with Walgreen perplexes Arcadia's investorsRestricted Content

January 21, 2012
J.K. Wall
Something doesn’t add up about Arcadia Resources Inc.’s agreement to sell its pharmacy business for a low price of $2 million, according to many of the Indianapolis company’s investors.
More

Lechleiter bets history will repeat for Lilly

January 16, 2012
J.K. Wall
Eli Lilly and Co. CEO John Lechleiter keeps pouring more money into research and development, even as analysts note the payoff of such spending has dropped off 70 percent in the last decade.
More

Drugmaker plans 234 Terre Haute jobs by 2016

January 10, 2012
 IBJ Staff and Associated Press
A California-based pharmaceutical company says it expects to hire 234 people by 2016 at a new operation on the site of a former Pfizer Inc. drug plant near Terre Haute.
More

Pressure rises as Lilly tries squeeze play

January 9, 2012
J.K. Wall
Indianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire, even as the company needs to spend more money on marketing and research to boost sales of new drugs.
More

Boston lawsuit claims DES-breast cancer link

January 8, 2012
Associated Press
Fifty-three women from around the country are suing drug companies, including Eli Lilly and Co., who made and promoted DES for millions of pregnant women from about 1938 to the early 1970s.
More

Lilly's 2012 earnings forecast misses analyst estimates

January 5, 2012
Bloomberg News, Associated Press
Indianapolis-based Eli Lilly and Co. provided a 2012 earnings forecast Thursday morning that missed analyst estimates by a wide margin, sending shares down.
More

Lilly challenging Biogen patent in London lawsuit

January 5, 2012
Bloomberg News
Eli Lilly and Co. has sued Biogen Idec Inc. in a London court to revoke a European patent on a potential treatment for immune-system diseases.
More

Lilly losing dominance in diabetes treatmentRestricted Content

December 31, 2011
J.K. Wall
Eli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses on other products that have begun to sap the drugmaker's sales.
More

Walgreen expects to lose most Express Scripts biz

December 29, 2011
Associated Press
Drugstore operator Walgreen Co. said Thursday it expects to lose almost 90 percent of prescriptions handled by pharmacy benefits manager Express Scripts Inc. after it leaves Express Scripts' networks on Jan. 1.
More

Arcadia agrees to sell DailyMed to Walgreen

December 27, 2011
J.K. Wall
It looks like Arcadia Resources Inc.’s DailyMed pharmacy business will live on—but under the wing of Walgreen Co. instead of on its own.
More

Endocyte shares plunge on clinical trial results

December 13, 2011
J.K. Wall
Shares of Endocyte Inc. plummeted more than 60 percent Tuesday morning after clinical trial results showed the company’s experimental ovarian cancer drug led to shorter survival times than treatment with a standard cancer drug.
More

Lilly shares rise on possibility for Alzheimer’s drug

December 7, 2011
Bloomberg News
Eli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s experimental Alzheimer’s drug could double the share price.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT